DalCor Pharmaceuticals is developing dalcetrapib, the first pharmacogenetic precision medicine targeting patients with the AA genotype at the rs1967309 location in the ADCY9 gene, to reduce the risk of fatal and non-fatal myocardial infarction following acute coronary syndrome. The ongoing Dal-GenE-2 Phase 3 trial aims to confirm a 21% relative risk reduction in cardiovascular events for this specific genetic subset.
Funding
$308.4M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Cardiovascular disease remains a leading global health burden, and current treatments may not be equally effective for all patients. Following an acute coronary syndrome (ACS) event, the risk of subsequent myocardial infarction (MI) remains a significant concern. Identifying patients who will benefit most from specific therapies is a challenge in cardiovascular medicine.
Solution
DalCor Pharmaceuticals is developing dalcetrapib, a precision medicine specifically for patients with the AA genotype at the rs1967309 location in the ADCY9 gene. This targeted approach aims to reduce the risk of fatal and non-fatal myocardial infarction (MI) following an acute coronary syndrome (ACS) event in this genetically defined subpopulation. Dalcetrapib has demonstrated a relative risk reduction in cardiovascular events in patients with the ADCY9 AA genotype. The ongoing Dal-GenE-2 Phase 3 trial is designed to confirm these findings in a larger cohort of post-ACS patients with the specified genetic marker.
Target Audience
The primary target audience is patients with a recent acute coronary syndrome (ACS) who also possess the AA genotype at the rs1967309 location in the ADCY9 gene.
Features
- Pharmacogenetic approach targeting the ADCY9 AA genotype at the rs1967309 location.
- Investigational drug, dalcetrapib, designed to reduce the risk of fatal and non-fatal myocardial infarction.
- Focus on patients following an acute coronary syndrome (ACS) event.
- Phase 3 clinical trial (Dal-GenE-2) underway to confirm efficacy.
- Previous dal-GenE trial showed a 21% relative risk reduction in fatal and non-fatal MI in patients with the target genotype.
- Good safety and tolerability profile observed in over 15,000 patients.